中文 | English
Return
Total: 240 , 1/24
Show Home Prev Next End page: GO
Author:(Hai-Zhen XU)

1.Related biomarkers in the diagnosis of prostate cancer.

Yi-min XU ; Hai-zhen LIU

National Journal of Andrology 2015;21(10):937-940

3.Effect of radiotherapy combined with interventional therapy on vascular endothelial growth factor in patients with advanced cervical cancer

Zhen LIU ; Xiaoyan SU ; Yan HU ; Hai XU

Chinese Journal of Biochemical Pharmaceutics 2016;36(11):112-114

4.Research Advance in Environmental Estrogens of Effluent from Sewage Treatment Plants

Hai-Zhen ZHANG ; Guang-Hua LU ; Shuai XU ;

Journal of Environment and Health 2007;0(08):-

5.Analysis and outlook on teaching status of Molecular Pharmacognosy.

Yu-xia BI ; Hai-yu XU ; Yan TONG ; Shu-zhen CUI ; Hai-yan LI ; Chang-xiao LIU

China Journal of Chinese Materia Medica 2015;40(17):3355-3359

6.Solidification of volatile oil with graphene oxide.

Hong-Mei YAN ; Xiao-Bin JIA ; Zhen-Hai ZHANG ; E SUN ; Yi-Hao XU

Acta Pharmaceutica Sinica 2015;50(2):222-226

7.Study on porous starch as solid dispersion carrier of total Epimedium flavonoids.

Hong-mei YAN ; Xiao-bin JIA ; Zhen-hai ZHANG ; E SUN ; Yi-hao XU

China Journal of Chinese Materia Medica 2015;40(9):1723-1726

8.Effect of suet oil on formation of self-assembled micelles of flavonoids in Epimedium.

Jie LI ; E SUN ; Zhen-hai ZHANG ; Jun JIANG ; Feng-juan XU ; Xiao-bin JIA

China Journal of Chinese Materia Medica 2014;39(17):3278-3282

9.Study on preparation of sagittatoside B with epimedin B converted from cellulase.

Feng-Juan XU ; E SUN ; Zhen-Hai ZHANG ; Li CUI ; Xiao-Bin JIA

China Journal of Chinese Materia Medica 2014;39(2):235-239

10.Clinical Observation of Exenatide Combined with Clomiphene Citrate in the Treatment of Polycystic Ova-ry Syndrome with Insulin Resistance

Hai XU ; Danfeng MA ; Jingling ZHAO ; Zhen MA ; Zhiyin WANG ; Haixia CHEN ; Guoyan MO

China Pharmacy 2017;28(12):1606-1609

Sort by Result Analysis

Display Mode

Output Records




File Type





Total: 240 , 1/24 Show Home Prev Next End page: GO